This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Preparation Rich in Growth Factors (PRGF) Treatment for Osteoarthritis of the Knee

This study has been completed.
Information provided by:
Meir Medical Center Identifier:
First received: August 3, 2008
Last updated: July 10, 2011
Last verified: July 2011
to evaluate the influence of PRGF treatment on patient suffering from OA knee

Condition Intervention Phase
Osteoarthritis of the Knee Biological: PRGF Drug: hyaluronic acid Drug: placebo Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: PRP as a Treatment for Knee Osteoarthritis - Randomized-double-blind-placebo Control Trail.

Resource links provided by NLM:

Further study details as provided by Meir Medical Center:

Primary Outcome Measures:
  • Improvment of symptomes [ Time Frame: 1 year ]

Estimated Enrollment: 60
Study Start Date: January 2008
Study Completion Date: March 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Biological: PRGF
intra auricular injection 6mg
Other Name: platelet-derived preparation rich in growth factors
Active Comparator: 2 Drug: hyaluronic acid
20 mg / 2 ml
Other Name: Arthrease
Placebo Comparator: 3 Drug: placebo
physiological water 3cc + lidocain 3cc
Other Name: seline 0.9% nacl

Detailed Description:
Autologous platelet-secreted growth factors (GFs) may have therapeutic effects in osteoarthritis (OA) capsular joints via multiple mechanisms. Our aim is to examine the effect of a platelet-derived preparation rich in growth factors (PRGFs) in OA knee

Ages Eligible for Study:   40 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age 40-75 years old
  • diagnosed Oa of the knee more then 1 year
  • no knee deformation

Exclusion Criteria:

  • mental of physical disabilities
  • pregnancy
  • deformities of the knee
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00728611

Meir Medical Center
Kfar Saba, Israel
Sponsors and Collaborators
Meir Medical Center
  More Information

Responsible Party: Omer Mei Dan, Meir Medical Center Identifier: NCT00728611     History of Changes
Other Study ID Numbers: 1000
Study First Received: August 3, 2008
Last Updated: July 10, 2011

Additional relevant MeSH terms:
Osteoarthritis, Knee
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Hyaluronic Acid
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Protective Agents processed this record on August 21, 2017